Standard BioTools Inc. (LAB) Price Prediction 2026–2050

Standard BioTools Inc. is a healthcare company that develops, manufactures, and sells instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through Proteomics and Genomics segments, offering instruments, consumables, and assays for clinical and diagnostic uses.

The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc.

The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Standard BioTools Inc. (LAB) is a Healthcare company currently trading at $1.03 with a market cap of $402.08M, and it ranks 3221 by market capitalization. The stock’s current level sits near the $1 range, reflecting a modest scale in its market segment.

All-time high and all-time low are $6.70 and $0.0742 respectively, illustrating substantial historical volatility. The 30-day range runs from $0.8805 to $1.20, with key technicals showing support at $0.88 and resistance at $1.06. RSI is 60, with SMA50 at $0.9522 and SMA200 at $1.22, and annualized volatility at 50%.

The price outlook from the forecast shows potential upside over time, with a neutral stance in the near term and stronger upside in later years.

The multi-year forecast shows a path from a 2026 average of $1.03 (min $0.88, max $1.43) to a 2030 average of $1.20 (min $0.9061, max $1.70) with neutral sentiment through 2030. By 2031 the outlook turns bullish, with an average of $1.40 and a 36% ROI (min $1.04, max $2.03). The bullish tone extends through 2032 ($1.54 avg, 49.9% ROI), 2033 ($1.61 avg, 56% ROI), and 2034 ($1.66 avg, 61.5% ROI), with 2035 showing $1.55 average and $2.39 max (50.8% ROI).

The forecast projects substantial upside beyond 2035, with 2040 averaging $2.28 and a 121.7% ROI (min $1.52, max $3.71), and by 2050 an average of $4.34 with a max of $7.65 and a 321.6% ROI. In this long horizon, sentiment is bullish. These numbers are estimates, not guarantees, and are subject to market risk and other uncertainties.